@inbook{0fd77859487f4f4dbbe381e607528a47,
title = "Sex, Drugs, and How to Deal with Criticism: The Case of Flibanserin",
abstract = "In 2015, the US Food and Drug Administration made the controversial decision to approve flibanserin as the first drug against problems of low female sexual desire. This approval has encountered many criticisms; in particular, it has been condemned as an exemplary instance of medicalization and disease-mongering, as lacking sufficient evidential support, and as targeting a highly problematic diagnosis (Hypoactive Sexual Desire Disorder). In this paper, we review these complaints and show that many of the issues in the flibanserin case stem from a failure to properly deal with criticism. We argue that a principle of uptake of criticism can help preventing bias in research and drug regulation and can be secured by institutional measures.",
keywords = "n/a OA procedure",
author = "Anke Bueter and Saana Jukola",
note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature Switzerland AG.",
year = "2020",
doi = "10.1007/978-3-030-29179-2_20",
language = "English",
isbn = "978-3-030-29178-5",
series = "Boston Studies in the Philosophy and History of Science",
publisher = "Springer",
pages = "451--470",
editor = "Adam LaCaze and Barbara Osimani",
booktitle = "Uncertainty in Pharmacology",
address = "Germany",
}